NCT07648043
Feasibilty and Acceptability of Amani
Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalSupportive careMassachusetts General HospitalInvestigator-initiated
~40 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Amani
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility
Measured over From enrollment to end of treatment (6 weeks)
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Adults (≥ 18 years) who are diagnosed with sickle cell disease
Primarily followed at the Massachusetts General Hospital (MGH) Sickle Cell Disease Center
Have ability to comprehend and speak English given Amani is currently only available in English.
Exclusion
Have severe psychiatric (psychotic disorder, bipoloar disorder) or cognitive impairment which the treating hematologist believes would preclude ability to participate in the clinical trial
What this trial measures
- FeasibilityFrom enrollment to end of treatment (6 weeks)
Amani will be feasible if ≥50% of eligible patients enroll and if ≥60% of enrolled participants complete the educational modules and attend ≥60% of Amani group sessions.